NexImmune マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Craig Jalbert

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	3.3yrs
取締役会の平均在任期間	3.5yrs

経営陣の近況

Recent updates

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Sep 07

Neximmune GAAP EPS of -$0.69 misses by $0.01

Aug 15

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

Jul 14

NexImmune: Selling For Under Cash Value

May 31

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

May 26

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Dec 19

CEO（最高経営責任者

Craig Jalbert (62 yo)

less than a year

在職期間

Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Trainer	Consultant	1.2yrs	US$1.35m	データなし
Craig Jalbert	President	less than a year	データなし	データなし
Karen Haslbeck	Head of Human Resources	no data	データなし	データなし
Daniel Bednarik	Senior Vice President of Molecular Engineering & Protein Design	7.5yrs	データなし	データなし
Robert Knight	Chief Medical Officer	3.8yrs	US$2.91m	0% $ 0
Chad Rubin	Senior Vice President of Corporate Affairs	3.6yrs	データなし	データなし
Jack Ragheb	Senior Vice President of Translational Science	3.3yrs	データなし	データなし
Matthew Schiller	Head of Business Development	3.3yrs	データなし	データなし

3.3yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: NEXIの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gerald Nepom	Chair of Autoimmune & Infectious Disease Scientific Advisory Board	2.8yrs	データなし	データなし
Jeffrey Weber	Chief Scientific Advisor	3.5yrs	データなし	データなし
Anil Rustgi	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Jonathan Schneck	Co-Chairman of Scientific Advisory Board	12.8yrs	データなし	データなし
Paul Richardson	Member of Scientific Advisory Board	no data	データなし	データなし
Marcela Maus	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Miguel-Angel Perales	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Kevan Herold	Member of Scientific Advisory Board and Autoimmune & Infectious Disease Scientific Advisory Board	3.5yrs	データなし	データなし
Juan Varela	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Michelle Krogsgaard	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Yi Lin	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Andreas Mackensen	Member of Scientific Advisory Board	3.5yrs	データなし	データなし

3.5yrs

平均在職期間

経験豊富なボード: NEXIの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

NexImmune マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

High number of new directors

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

Independent Chairman of the Board recently bought US$164k worth of stock

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Recent updates

The Nasdaq Stock Market to Delist Common Stock of NexImmune

Nasdaq Determines to Delist NexImmune Shares of Common Stock

Nasdaq Determines to Delist NexImmune Shares of Common Stock

NexImmune, Inc. announced delayed 10-Q filing

NexImmune, Inc. announced delayed annual 10-K filing

High number of new directors

NexImmune, Inc. has completed a Follow-on Equity Offering in the amount of $3.672009 million.

NexImmune Receives Notice from Nasdaq Pursuant to Nasdaq Listing Rule 5101

NexImmune, Inc. announced delayed 10-Q filing

NexImmune Regains Compliance with the Minimum Closing Bid Price Requirement

NexImmune, Inc. Approves 1 for 25 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

New major risk - Financial position

Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting

Independent Chairman of the Board recently bought US$164k worth of stock

Price target decreased by 30% to US$2.43

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Price target decreased to US$2.43

High number of new directors

NexImmune Receives Deficiency Letter from the Listing Qualifications Department of Nasdaq

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Neximmune GAAP EPS of -$0.69 misses by $0.01

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune, Inc.(NasdaqGM:NEXI) dropped from Russell 2500 Value Index

Independent Director recently bought US$298k worth of stock

Price target decreased to US$14.75

NexImmune: Selling For Under Cash Value

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

NexImmune Inc. Appoints Leena Gandhi to Board of Directors as a Non-Executive Director

NexImmune, Inc., Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Neximmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

Neximmune, Inc. Promotes Mathias Oelke, Ph.D., to Chief Scientific Officer

NexImmune, Inc. Announces Management Changes

Independent Director exercised options to buy US$338k worth of stock.

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Independent Director has left the company

NexImmune, Inc. has completed an IPO in the amount of $110.007 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

マネジメント基準チェック /24